Roivant Sciences Ltd (FRA:87S)
€ 11.525 0.15 (1.32%) Market Cap: 8.62 Bil Enterprise Value: 3.56 Bil PE Ratio: 2.21 PB Ratio: 1.78 GF Score: 60/100

Roivant Sciences Ltd at Jefferies London Healthcare Conference Transcript

Nov 15, 2023 / 01:30PM GMT
Release Date Price: €8.2 (+1.23%)
Unidentified Analyst

I'm very pleased to have Roivant here and CEO, Matt Gline. So I mean, obviously, there has been -- there have been a lot of developments this year to the positive. The company has clearly been executing across the pipeline, including deals that have been done.

Questions & Answers

Unidentified Analyst

So maybe to level set everybody here in the room. Just remind us of all of the different developments and updates that you guys had this year? And sort of how should we think about the outlook through the end of the year?

Matthew Gline
Roivant Sciences Ltd. - CEO & Director

Yes, perfect. It's actually a nice bookend because I just think back to literally a year ago at this conference. And a year ago at this conference, the biggest things in our world is we had recently announced preclinical data for our next-generation anti-FcRn antibody. And what I knew, but nobody else did is that we were on the cusp of acquiring an anti-TL1A antibody.

We have not yet generated any atopic dermatitis. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot